Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

A deep learning-informed interpretation of why and when dose metrics outside the PTV can affect the risk of distant metastasis in SBRT NSCLC patients

D. Dudas, TJ. Dilling, IE. Naqa

. 2024 ; 19 (1) : 127. [pub] 20240927

Language English Country England, Great Britain

Document type Journal Article

Grant support
R01-CA233487 NIH HHS - United States
R01-CA233487 NIH HHS - United States
R01-CA233487 NIH HHS - United States
W81XWH-22-1-0277 Congressionally Directed Medical Research Programs
W81XWH-22-1-0277 Congressionally Directed Medical Research Programs
W81XWH-22-1-0277 Congressionally Directed Medical Research Programs

PURPOSE: Recent papers suggested a correlation between the risk of distant metastasis (DM) and dose outside the PTV, though conclusions in different publications conflicted. This study resolves these conflicts and provides a compelling explanation of prognostic factors. MATERIALS AND METHODS: A dataset of 478 NSCLC patients treated with SBRT (IMRT or VMAT) was analyzed. We developed a deep learning model for DM prediction and explainable AI was used to identify the most significant prognostic factors. Subsequently, the prognostic power of the extracted features and clinical details were analyzed using conventional statistical methods. RESULTS: Treatment technique, tumor features, and dosiomic features in a 3 cm wide ring around the PTV (PTV3cm) were identified as the strongest predictors of DM. The Hazard Ratio (HR) for Dmean,PTV3cm was significantly above 1 (p < 0.001). There was no significance of the PTV3cm dose after treatment technique stratification. However, the dose in PTV3cm was found to be a highly significant DM predictor (HR > 1, p = 0.004) when analyzing only VMAT patients with small and spherical tumors (i.e., sphericity > 0.5). CONCLUSIONS: The main reason for conflicting conclusions in previous papers was inconsistent datasets and insufficient consideration of confounding variables. No causal correlation between the risk of DM and dose outside the PTV was found. However, the mean dose to PTV3cm can be a significant predictor of DM in small spherical targets treated with VMAT, which might clinically imply considering larger PTV margins for smaller, more spherical tumors (e.g., if IGTV > 2 cm, then margin ≤ 7 mm, else margin > 7 mm).

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018844
003      
CZ-PrNML
005      
20241024111115.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13014-024-02519-1 $2 doi
035    __
$a (PubMed)39334387
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Dudas, D $u Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Prague, Czechia. dudasden@fjfi.cvut.cz
245    12
$a A deep learning-informed interpretation of why and when dose metrics outside the PTV can affect the risk of distant metastasis in SBRT NSCLC patients / $c D. Dudas, TJ. Dilling, IE. Naqa
520    9_
$a PURPOSE: Recent papers suggested a correlation between the risk of distant metastasis (DM) and dose outside the PTV, though conclusions in different publications conflicted. This study resolves these conflicts and provides a compelling explanation of prognostic factors. MATERIALS AND METHODS: A dataset of 478 NSCLC patients treated with SBRT (IMRT or VMAT) was analyzed. We developed a deep learning model for DM prediction and explainable AI was used to identify the most significant prognostic factors. Subsequently, the prognostic power of the extracted features and clinical details were analyzed using conventional statistical methods. RESULTS: Treatment technique, tumor features, and dosiomic features in a 3 cm wide ring around the PTV (PTV3cm) were identified as the strongest predictors of DM. The Hazard Ratio (HR) for Dmean,PTV3cm was significantly above 1 (p < 0.001). There was no significance of the PTV3cm dose after treatment technique stratification. However, the dose in PTV3cm was found to be a highly significant DM predictor (HR > 1, p = 0.004) when analyzing only VMAT patients with small and spherical tumors (i.e., sphericity > 0.5). CONCLUSIONS: The main reason for conflicting conclusions in previous papers was inconsistent datasets and insufficient consideration of confounding variables. No causal correlation between the risk of DM and dose outside the PTV was found. However, the mean dose to PTV3cm can be a significant predictor of DM in small spherical targets treated with VMAT, which might clinically imply considering larger PTV margins for smaller, more spherical tumors (e.g., if IGTV > 2 cm, then margin ≤ 7 mm, else margin > 7 mm).
650    _2
$a lidé $7 D006801
650    12
$a nemalobuněčný karcinom plic $x radioterapie $x patologie $7 D002289
650    12
$a nádory plic $x patologie $x radioterapie $7 D008175
650    12
$a deep learning $7 D000077321
650    12
$a radiochirurgie $x metody $7 D016634
650    12
$a celková dávka radioterapie $7 D011879
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a radioterapie s modulovanou intenzitou $x metody $7 D050397
650    _2
$a prognóza $7 D011379
650    _2
$a plánování radioterapie pomocí počítače $x metody $7 D011880
650    _2
$a senioři $7 D000368
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metastázy nádorů $7 D009362
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dilling, T J $u Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
700    1_
$a Naqa, I El $u Department of Machine Learning, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
773    0_
$w MED00165460 $t Radiation oncology (London, England) $x 1748-717X $g Roč. 19, č. 1 (2024), s. 127
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39334387 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111109 $b ABA008
999    __
$a ok $b bmc $g 2201609 $s 1230817
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 19 $c 1 $d 127 $e 20240927 $i 1748-717X $m Radiation oncology (London, England) $n Radiat Oncol $x MED00165460
GRA    __
$a R01-CA233487 $p NIH HHS $2 United States
GRA    __
$a R01-CA233487 $p NIH HHS $2 United States
GRA    __
$a R01-CA233487 $p NIH HHS $2 United States
GRA    __
$a W81XWH-22-1-0277 $p Congressionally Directed Medical Research Programs
GRA    __
$a W81XWH-22-1-0277 $p Congressionally Directed Medical Research Programs
GRA    __
$a W81XWH-22-1-0277 $p Congressionally Directed Medical Research Programs
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...